{"id":36584,"date":"2015-07-15T09:07:16","date_gmt":"2015-07-15T13:07:16","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=36584"},"modified":"2015-07-15T09:07:16","modified_gmt":"2015-07-15T13:07:16","slug":"johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584","title":{"rendered":"Johnson &#038; Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Johnson &amp; Johnson (NYSE:JNJ)<\/strong> might successfully reopen its Non-prescription medicines business that was shut down initially due to recalls.<\/p>\n<p style=\"text-align: justify;\">Over the past few years, the business suffered due to numerous recalls for some of its products. The company called back more than 135 million medicine bottles after tiny chunks of metal was discovered in Tylenol, one of the medicines for children. The event took place in 2010 and since then, the company has spent millions to upgrade the plant. The company recently announced that its refurbished plant recently underwent the necessary inspection by the Food and Drug Administration.<\/p>\n<p style=\"text-align: justify;\">The recall were extremely detrimental to the company and, as a result, the firm suffered huge losses. Johnson &amp; Johnson (NYSE:JNJ) CHIEF Executive, Alex Gorsky feels that the company has made a lot of progress in reversing the negative image that the business suffered. One of the company\u2019s spokespersons claims that the FDA has not set a specific reopening timetable for the plant. J&amp;J reported second quarter profits amounting to $4.5 billion, or $1.61 a share compared to $4.3 billion, or $1.51 a share in the previous year, thus a significant improvement.<\/p>\n<p style=\"text-align: justify;\">In the current financial year, revenues have so far dropped from 8.8% to $17.79 billion mostly due to the effect of the strong dollar. The company has also been under heavy competition from other pharmaceutical companies, especially for the Hepatitis C treatments. One of the biggest competitors is <strong>Gilead Sciences, Inc. (NASDAQ:GILD)<\/strong><strong>\u00a0<\/strong>with a lucrative new treatment that rivals J&amp;J\u2019s Olysio.<\/p>\n<p style=\"text-align: justify;\">Sandra Peterson is the executive overseeing J&amp;J\u2019s return to the consumer health business. Ms. Peterson claims that 80% of the brandsthat were withdrawn from the market after the incidence will make a comeback. The company plans on regaining the huge market share that it had acquired before the Non-prescription medicines business went belly-up. Ms. Peterson also revealed that the company already has approval from the FDA to reopen the Fort Washington plant and two others in Lancaster, Pa and Las Piedras, Puerto Rico.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (NYSE:JNJ) might successfully reopen its Non-prescription medicines business that was shut down initially due to recalls. Over the past few years, the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":24973,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[11590,1978,1744,1522,995],"stock_ticker":[],"class_list":["post-36584","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-alex-gorsky","tag-gilead-sciences-inc-nasdaqgild","tag-johnson-johnson-nysejnj","tag-nasdaqgild","tag-nysejnj","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Johnson &amp; Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (NYSE:JNJ) might successfully reopen its Non-prescription medicines business that was shut down initially due to recalls. Over the past few years, the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-15T13:07:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"728\" \/>\n\t<meta property=\"og:image:height\" content=\"414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Johnson &#038; Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business\",\"datePublished\":\"2015-07-15T13:07:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584\"},\"wordCount\":347,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg\",\"keywords\":[\"Alex Gorsky\",\"Gilead Sciences Inc (NASDAQ:GILD)\",\"Johnson &amp; Johnson (NYSE:JNJ)\",\"NASDAQ:GILD\",\"NYSE:JNJ\"],\"articleSection\":[\"Business\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584\",\"name\":\"Johnson & Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg\",\"datePublished\":\"2015-07-15T13:07:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg\",\"width\":728,\"height\":414},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson &#038; Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Johnson & Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584","og_locale":"en_US","og_type":"article","og_title":"Johnson & Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business - Wall Street PR","og_description":"Johnson &amp; Johnson (NYSE:JNJ) might successfully reopen its Non-prescription medicines business that was shut down initially due to recalls. Over the past few years, the [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-07-15T13:07:16+00:00","og_image":[{"width":728,"height":414,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Johnson &#038; Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business","datePublished":"2015-07-15T13:07:16+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584"},"wordCount":347,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg","keywords":["Alex Gorsky","Gilead Sciences Inc (NASDAQ:GILD)","Johnson &amp; Johnson (NYSE:JNJ)","NASDAQ:GILD","NYSE:JNJ"],"articleSection":["Business","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584","url":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584","name":"Johnson & Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg","datePublished":"2015-07-15T13:07:16+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Johnson-Johnson.jpg","width":728,"height":414},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/johnson-johnson-nysejnj-to-revive-its-non-prescription-medicines-business-36584#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Johnson &#038; Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=36584"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36584\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/24973"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=36584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=36584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=36584"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=36584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}